Seed and early stage investments in exceptional technology and life sciences companies.


Redalpine news

Redbiotec and GE Healthcare Collaborate (30/07/2014)
Redbiotec (Redalpine Capital I), a biopharmaceutical company specializing in vaccine development, has successfully applied its unique expertise and innovative technology platform to complete a collaborative program with global multinational, GE Healthcare Life Sciences. Using GE Healthcare’s single-use WAVE Bioreactor and ReadyToProcess crossflow filtration system, the team developed a novel process for the production, clarification, and [...] More.

Redalpine leads seven-figure funding round for online art platform Juniqe (17/07/2014)
Redalpine is delighted to announce an investment in Berlin-based Juniqe, the up-and-coming e-commerce platform for affordable art. The seven-figure funding round, led by Redalpine with co-investments by High-Tech Gründerfonds, German Startups Group and business angels, will help the company strengthen its international position and accelerate their already impressive growth. There is great demand for affordable [...] More.

InSphero Enters into Collaboration with Protea Biosciences and Wins ‘Startup of the Year’ Award (10/07/2014)
InSphero AG (Redalpine Capital I) and Protea Biosciences Group, Inc. (OTCQB:PRGB) jointly announced that they have entered into a collaboration that will combine each company’s respective 3D technology. InSphero AG is the leading supplier of 3D organotypic microtissues for in vitro toxicology and efficacy studies, with models derived from liver, pancreas, tumor, and brain tissue [...] More.

More More Redalpine news

Industry news

What investors say

"To evaluate the potential of a new idea requires experience and a clear understanding of the products and market dynamics. We trust in the team of Redalpine to master this challenge successfully."
Jürg Staub, General Partner, Reichmuth & Co, Privatbankiers
"Switzerland's future standard of living will largely depend on its ability to remain a player at the top of technological progress. Too many revolutionary ideas of our top universities have to emigrate to Silicon Valley to find early stage venture capital or remain in the drawers. Redalpine is active in this early stage where the need is most urgent and the potential gain the highest."
Dr. Henri B. Meier, former CFO Roche, Founder of HBM BioVentures

More More investor quotes

Connect with us

Subscribe to our news

Find us on Facebook

Find us on Twitter

Find us on LinkedIn